Evidence map›Paper›PMID 29298347›Full record

ArticlePloS one2018

Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling.

Martin Grundy, Claire Seedhouse, Thomas Jones, Liban Elmi, Michael Hall, Adam Graham, Nigel Russell, Monica Pallis

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Martin GrundyClinical Haematology, Nottingham University Hospitals, Nottingham, United Kingdom.ORCID 0000-0002-0719-2469
Claire SeedhouseDepartment of Haematology, Division of Cancer and Stem Cells, University of Nottingham, Nottingham, United Kingdom.
Thomas JonesDepartment of Haematology, Division of Cancer and Stem Cells, University of Nottingham, Nottingham, United Kingdom.
Liban ElmiDepartment of Haematology, Division of Cancer and Stem Cells, University of Nottingham, Nottingham, United Kingdom.
Michael HallDepartment of Haematology, Division of Cancer and Stem Cells, University of Nottingham, Nottingham, United Kingdom.
Adam GrahamDepartment of Haematology, Division of Cancer and Stem Cells, University of Nottingham, Nottingham, United Kingdom.
Nigel RussellClinical Haematology, Nottingham University Hospitals, Nottingham, United Kingdom.
Monica PallisClinical Haematology, Nottingham University Hospitals, Nottingham, United Kingdom.
University of Nottingham · GBNottingham University Hospitals NHS Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The BH3-only apoptosis agonists BAD and NOXA target BCL-2 and MCL-1 respectively and co-operate to induce apoptosis. On this basis, therapeutic drugs targeting BCL-2 and MCL-1 might have enhanced activity if used in combination. We identified anti-leukaemic drugs sensitising to BCL-2 antagonism and drugs sensitising to MCL-1 antagonism using the technique of dynamic BH3 profiling, whereby cells were primed with drugs to discover whether this would elicit mitochondrial outer membrane permeabilisation in response to BCL-2-targeting BAD-BH3 peptide or MCL-1-targeting MS1-BH3 peptide. We found that a broad range of anti-leukaemic agents-notably MCL-1 inhibitors, DNA damaging agents and FLT3 inhibitors-sensitise leukaemia cells to BAD-BH3. We further analysed the BCL-2 inhibitors ABT-199 and JQ1, the MCL-1 inhibitors pladienolide B and torin1, the FLT3 inhibitor AC220 and the DNA double-strand break inducer etoposide to correlate priming responses with co-operative induction of apoptosis. ABT-199 in combination with pladienolide B, torin1, etoposide or AC220 strongly induced apoptosis within 4 hours, but the MCL-1 inhibitors did not co-operate with etoposide or AC220. In keeping with the long half-life of BCL-2, the BET domain inhibitor JQ1 was found to downregulate BCL-2 and to prime cells to respond to MS1-BH3 at 48, but not at 4 hours: prolonged priming with JQ1 was then shown to induce rapid cytochrome C release when pladienolide B, torin1, etoposide or AC220 were added. In conclusion, dynamic BH3 profiling is a useful mechanism-based tool for understanding and predicting co-operative lethality between drugs sensitising to BCL-2 antagonism and drugs sensitising to MCL-1 antagonism. A plethora of agents sensitised cells to BAD-BH3-mediated mitochondrial outer membrane permeabilisation in the dynamic BH3 profiling assay and this was associated with effective co-operation with the BCL-2 inhibitory compounds ABT-199 or JQ1.

Indexed as

Antineoplastic AgentsApoptosisAzepinesBridged Bicyclo Compounds, HeterocyclicCell Line, TumorDrug CombinationsHumansIndolesLeukemiaMyeloid Cell Leukemia Sequence 1 ProteinProto-Oncogene Proteins c-bcl-2SulfonamidesTriazolesA-1210477Antineoplastic AgentsAzepinesBridged Bicyclo Compounds, HeterocyclicDrug CombinationsIndoles(+)-JQ1 compoundMyeloid Cell Leukemia Sequence 1 ProteinProto-Oncogene Proteins c-bcl-2SulfonamidesTriazolesvenetoclax

Identifiers

PMID29298347
PMCPMC5752038
OpenAlexW2782407913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.